Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Neuroendocrine carcinoma
Stage/Subtype:  thyroid gland medullary carcinoma
Trial Type:  Treatment
Results 1-15 of 15 for your search:
Start Over
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CSOM230B2412, NCI-2017-01247, NCT01794793
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: SCRX001-006, NCI-2016-01071, NCT02709889
Alectinib in Treating Patients with RET-Rearranged Stage IIIB-IV Non-small Cell Lung Cancer or RET-Mutated Stage IV Thyroid Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17-080, NCI-2017-01201, NCT03131206
Vaccine Therapy in Treating Patients with Recurrent or Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0095, NCI-2013-01587, 1301-1199, GI-6207, GI-6207-02, P11934, RD-13-I-10, NCT01856920
Regorafenib in Treating Patients with Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-350, NCI-2016-00333, NCT02657551
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E7080-M000-213, NCI-2016-01668, NCT02657369
Pembrolizumab in Treating Patient with Recurrent or Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 17-C-0061, NCI-2017-00393, NCT03072160
Pembrolizumab in Treating Patients with Previously Treated Metastatic High Grade Neuroendocrine Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GI-087, NCI-2016-01492, NCT02939651
Cyclophosphamide and Sirolimus and in Treating Patients with Metastatic, Radioiodine-Refractory Thyroid Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2017.013, NCI-2017-00759, HUM00126559, NCT03099356
Trametinib in Treating Patients with Solid Tumors, Metastatic Medullary Thyroid Cancer or Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-0146, NCI-2017-01026, NCT02363647
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, 17-C-0012, NCT02631733
Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BLU-667-1101, NCI-2017-00300, 2016-004390-41, NCT03037385
Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-RET-17001, NCI-2017-00976, 2017-000800-59, NCT03157128
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: XL184-209, NCI-2012-02141, NCT01683110
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients with Metastatic Endocrine Cancer
Status: Active
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2014-0864, NCI-2015-02058, NCT02592356
Start Over